OpportunityAnalyzer: Pancreatic Cancer - Opportunity Analysis and Forecasts to 2017


Published on

Market Research Reports, Inc. has announced the addition of “OpportunityAnalyzer: Pancreatic Cancer - Opportunity Analysis and Forecasts to 2017” research report to their offering. See more at: http://mrr.cm/ZU2

Published in: Business, Health & Medicine
  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

OpportunityAnalyzer: Pancreatic Cancer - Opportunity Analysis and Forecasts to 2017

  1. 1. www.MarketResearchReports.com Category : Pharma & Healthcare All logos and Images mentioned on this slide belong to their respective owners.
  2. 2. www.MarketResearchReports.com Introduction to Report  Launch Date: March 27, 2014  Number of Pages: 179  Geography Coverage: Global  Available Format: PDF Price For Single User License: USD 5,995 Price For Site User License: USD 11,990 Price For Global User License: USD 17,985 Delivery Time: Within 24 Hours (During Working Days)
  3. 3. www.MarketResearchReports.com About the Report OpportunityAnalyzer: Pancreatic Cancer Opportunity Analysis and Forecasts to 2017 report focuses on the current treatment landscape, unmet needs, pipeline and commercial opportunity in the pancreatic cancer market with coverage of both the early stage resectable and advanced settings. Celgene’s Abraxane was launched in the US and Europe in 2013 and 2014, respectively, and was the first drug approved in this disease in nearly a decade. Due to the high unmet need, Publisher forecasts the rapid uptake of Abraxane, and sales of this drug are expected to drive the overall pancreatic cancer market and are forecast to represent greater than 50% of total market sales in 2017.
  4. 4. www.MarketResearchReports.com Research Findings Publisher estimates that the value of the pancreatic cancer market in the US and 5EU (France, Germany, Italy, Spain, and the UK) in 2012 was $529m. This market is defined as sales of branded drugs and major generic regimens commonly prescribed for pancreatic cancer patients across the six major markets (6MM). Just over half of these sales, $275m (52%), were generated in the US, while sales in the 5EU were estimated at $254m (48%). By 2017, the end of the forecast period, Publisher projects pancreatic cancer sales to rise to $1.63 billion in the US and 5EU, at a high Compound Annual Growth Rate (CAGR) of 25.2%. Publisher expects the proportion of sales from the US to increase to 72%, with market share in the 5EU decreasing to 28% by 2017. Publisher forecasts sales of Abraxane to rise significantly, from $21m in 2012 to $954m in 2017, at a CAGR of 115%; sales of Abraxane will represent nearly 60% of the pancreatic cancer market by the end of the forecast period
  5. 5. www.MarketResearchReports.com Scope Overview of pancreatic cancer, including epidemiology, etiology, pathophysiology, symptoms, prognosis, and clinical staging. Topline pancreatic cancer therapeutics market revenue from 2012–2017. Annual cost of therapy, and major marketed and pipeline drug sales in this forecast period are included. Key topics covered include strategic competitor assessment, market characterization, unmet needs, R&D strategies, and clinical trial design for the pancreatic cancer therapeutics market.
  6. 6. www.MarketResearchReports.com Scope Continues… Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline drugs. An interactive clinical and commercial analyzer tool is available. Analysis of the current and future market competition in the 6MM pancreatic cancer therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
  7. 7. www.MarketResearchReports.com Reasons To Buy Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Develop business strategies by understanding the trends shaping and driving the 6MM pancreatic cancer market. Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 6MM pancreatic cancer therapeutics market in the future. Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors. Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  8. 8. www.MarketResearchReports.com Report Coverage Table of Contents Introduction Disease Overview Epidemiology Current Treatment Options Unmet Needs Assessment and Opportunity Analysis Research and Development Strategies Pipeline Assessment Pipeline Valuation Analysis Appendix
  9. 9. www.MarketResearchReports.com Custom Research:  Are you an industry professional, entrepreneur, venture capitalist, investors and organization, then let us know your specific research requirements. Our goal is to cater to your requirements be it for a custom market research project, syndicated research report on a specific market or industry sector, newsletter creation, case study development or anything else related to marketing research. For Any Customization Related query Visit IdeaCenter @ http://www.marketresearchreports.com/idea-center
  10. 10. www.MarketResearchReports.com How To Buy This Report? Visit following URL to see Table of Content and purchase this publication: http://mrr.cm/ZU2 About Market Research Reports, Inc. Market Research Reports provides a customized set of reports from reputed Publishers, built on the intelligence available within organizations and leverages on our motto of “Intelligence Redefined”. Contact : Amitava Sen Email : info@marketresearchreports.com Phone: +1 302-703-7787 (USA) +91-8762746600 (India)